Alcon
ALC Healthcare Medical Instruments & Supplies
Alcon’s revenue for fiscal 2025 (year ended December 2025) was $10.4 billion, up 4.94% from fiscal 2024. In the quarter to June 2026, revenue grew 8.74%, EPS fell 100.0%, free cash flow was flat and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow ALC
Alcon (ALC) EV/Sales
As of 16 October 2026, Alcon (ALC) trades at a EV/Sales of 3.3×. Over the past ten years it has ranged from 0.0× (June 2019) to 5.8× (September 2021); the current reading is higher than 5% of that period. That is above the Medical Instruments & Supplies industry median of 2.9× and in line with the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 4.0× | (10.64%) |
| FY2024 | 4.5× | 2.64% |
| FY2023 | 4.4× | 2.16% |
| FY2022 | 4.3× | (20.94%) |
| FY2021 | 5.5× | 6.95% |
| FY2020 | 5.1× | 26.39% |
| FY2019 | 4.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.3× | (11.60%) |
| Mar 2026 | 3.7× | (7.35%) |
| Dec 2025 | 4.0× | 2.86% |
| Sep 2025 | 3.9× | (16.36%) |
| 28 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MDLN Medline Inc. compare | 1.4× |
| BAX Baxter International Inc. compare | 1.8× |
| SOLV Solventum Corporation compare | 2.4× |
| BDX Becton, Dickinson and Company compare | 2.9× |
| COO The Cooper Companies, Inc. compare | 3.2× |
| ALC Alcon | 3.3× |
| RMD ResMed Inc. compare | 6.0× |
| WST West Pharmaceutical Services, Inc. compare | 8.1× |
| RGEN Repligen Corporation compare | 12.3× |
| Medical Instruments & Supplies industry median | 2.9× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)